THE FUTURE OF DIAGNOSTICS
Accurate, rapid, digital detection of infection in bodily fluids to indicate in real-time which drugs will be most effective at the point-of-prescription.
The U.S. market for detecting infection exceeds $20 billion annually, providing a significant opportunity for companies that provide accurate and more efficient infectious disease diagnostics. Avails technology serves the existing market by enabling incumbent market leaders to improve their existing workflow. Providing antibiotic susceptibility data to physicians as soon as possible at the point-of-prescription to inform their therapeutic decisions is critical to improving health outcomes.
Avails is also developing intuitive, streamlined, standalone applications, all based on its propriety electrical biosensor platform. Applications will include electrical pathogen quantification, antibiotic susceptibility testing (AST) and identification of certain forms of resistance expressed in bacteria and fungi. Complimentary to current rapid pathogen identification technologies, Avails cost-effective platform will advance the diagnostics market by enabling for the first time diagnostic-guided therapy at the point-of-prescription, meaningfully reducing the time to treatment. For the majority of infectious disease diagnoses, Avails is expected to reduce treatment decisions from days to several hours.